Application Detail
Description of Medical Service
Genetic testing for BRCA1 and BRCA2 mutations in patients with platinum-sensitive relapsed ovarian cancer, to determine PBS eligibility for treatment with olaparib (co-dependent technology)Description of Medical Condition
Ovarian cancer is the tenth most common cancer in Australian women, and the second most common gynaecological cancer. The symptoms for ovarian cancer tend to be vague and non-specific. The majority of women with ovarian cancer are diagnosed at an advanced stage after the tumour has spread to other organs, with the prognosis associated with advanced ovarian cancer being limited.Reason for Application
New MBS itemMedical Service Type
Co-dependent technologyPrevious Application Number
Not ApplicableAssociated Documentation
Application Form
-PICO Confirmation
Final Protocol - Ratified (PDF 402 KB)Final Protocol - Ratified (Word 663 KB)
Assessment Report
-Public Summary Document
Public Summary Document (PDF 165 KB)Public Summary Document (Word 118 KB)
Consumer Friendly Public Summary Document (PSD)
Consumer Friendly PSD (PDF 255 KB)Consumer Friendly PSD (Word 18 KB)
Consumer Friendly PSDs - The Basics
The Basics (PDF 190 KB)The Basics (Word 29 KB)
Meetings for this Application
PASC
14 - 15 August 201411 - 12 December 2014
ESC
10 - 11 February 2016MSAC
30 - 31 March 201624 - 25 November 2016